EUCTR2006-003484-31-NL进行中（未招募）不适用
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HME
Eli Lilly and Company Ltd.0 个研究点目标入组 230 人开始时间: 2006年10月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female outpatients at least 18 years of age with chronic low back pain as their primary painful condition.
- •Based upon medical history, neurological examination and medical records, have low back pain (T-6 or below) present on most days for the preceding 6 months or longer and fulfill all disease diagnostic criteria).
- •Have a weekly mean of 24-hour average pain score greater than or equal to 4 (average of 24-hour pain assessments recorded in the electronic patient diary during the last week before randomization, on a 0 to 10 scale, where 0 is no pain and 10 is worst possible pain).
- •Females of child-bearing potential must test negative on a pregnancy test at Visit 1. Females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopause) must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study. Examples of reliable methods include use of oral contraceptives or Depo-Provera® Contraceptive Injection (sterile medroxyprogesterone acetate suspension, Pharmacia & Upjohn), partner with vasectomy, abstinence, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices. Women who are pregnant or breast-feeding may not participate in the study.
- •Have education level and degree of understanding such that they can communicate intelligibly with the investigator and study coordinator.
- •Are judged by the investigator to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- •Are Lilly or Boehringer Ingelheim (BI) employees.
- •Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •Have a history of more than 1 low back surgery.
- •Have a history of low back surgery within 12 months prior to study entry.
- •Have received epidural steroids, facet block, nerve block or other invasive procedures aimed to reduce low back pain within the past month prior to Visit 1.
- •Have previously completed or withdrawn from this study or any other study investigating duloxetine hydrochloride.
- •Completion of the daily diaries for less than 70% of the days between Visit 1 and Visit 2.
- •Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder.
- •Have major depressive disorder as determined using depression module of the Mini International Neuropsychiatric Interview (MINI).
- •Anticipated by the investigator to require use of opioid analgesics or other protocol-excluded medication for the duration of the study.
- •Have ongoing or anticipated disability compensation or litigation issues, in the best judgement of the investigator.
- •Have a presence of any factors/conditions, medical or other, that in the judgment of the investigator may interfere with performance of study outcome measures, such as treatment-refractory history.
- •Are judged clinically by the investigator to be at suicidal risk or as identified by a score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II) prior to starting study drug.
- •Have a positive urine drug screen for any substances of abuse or excluded medication (including but not limited to narcotics, barbiturates, amphetamines, benzodiazepines).
- •Have acute liver injury (such as hepatitis) or severe cirrhosis (Child- Pugh Class C).
- •Have a body mass index (BMI) over 40.
- •Have uncorrected thyroid disease, uncontrolled narrow-angle glaucoma, history of uncontrolled seizures, or uncontrolled or poorly controlled hypertension.
- •Have had previous exposure to duloxetine.
- •Have serious or unstable cardiovascular, hepatic, renal, metabolic, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or other medical condition or psychiatric conditions that, in the opinion of investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
- •Have known hypersensitivity to duloxetine, to its inactive ingredients, or to multiple other medications.
- •Are taking any excluded medications that cannot be discontinued at Visit 1.
- •Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of Visit 2 or the potential need to use and MAOI during the study or within 5 days of discontinuation of study drug.
- •Are non-ambulatory or require the use of crutches or a walker.
- •Have a history of substance abuse or dependence within the past year, excluding nicotine and caffeine.
- •Are pregnant or breast-feeding.
研究者
相似试验
进行中（未招募）
1 期
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HMEChronic Low Back PainMedDRA version: 8.1Level: LLTClassification code 10003988Term: Back painEUCTR2006-003484-31-FREli Lilly and Company Ltd.230
进行中（未招募）
不适用
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HMEChronic Low Back PainMedDRA version: 8.1Level: LLTClassification code 10003988Term: Back painEUCTR2006-003484-31-DEEli Lilly and Company Ltd.230
已完成
3 期
Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back PaiNL-OMON32370Eli Lilly30
进行中（未招募）
不适用
Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pain - HMGCChronic low back pain (CLBP)MedDRA version: 9.1Level: LLTClassification code 10024891Term: Low back painEUCTR2008-002248-40-NLEli Lilly and Company400
进行中（未招募）
不适用
Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pain - HMGCChronic low back pain (CLBP)MedDRA version: 9.1Level: LLTClassification code 10024891Term: Low back painEUCTR2008-002248-40-DEEli Lilly and Company400